At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Antigouts
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gout; Hyperuricaemia
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 20 Mar 2006 Y 700 is available for licensing worldwide (http://www.micusa.com)
- 10 Nov 2005 Phase-II clinical trials in Gout in Japan (PO)